淋巴管生成：癌症进展的新角色。
Lymphangiogenesis: a new player in cancer progression.
机构信息
Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine and Massey Cancer Center, West Hospital,1200 East Broad Street, Richmond, VA 23298-0011, USA.
出版信息
World J Gastroenterol. 2010 Aug 28;16(32):4003-12. doi: 10.3748/wjg.v16.i32.4003.
Lymph node metastasis is the hallmark of colon cancer progression, and is considered one of the most important prognostic factors. Recently, there has been growing evidence that tumor lymphangiogenesis (formation of new lymphatic vessels) plays an important role in this process. Here, we review the latest findings of the role of lymphangiogenesis in colorectal cancer progression, and discuss its clinical application as a biomarker and target for new therapy. Understanding the molecular pathways that regulate lymphangiogenesis is mandatory to pave the way for the development of new therapies for cancer. In the future, tailored treatments consisting of combinations of chemotherapy, other targeted therapies, and anti-lymphangiogenesis agents will hopefully improve patient outcomes. This progression to the clinic must be guided by new avenues of research, such as the identification of biomarkers that predict response to treatment.
淋巴结转移是结肠癌进展的标志，被认为是最重要的预后因素之一。最近有越来越多的证据表明，肿瘤淋巴管生成（新淋巴管的形成）在这个过程中起着重要作用。在这里，我们回顾了淋巴管生成在结直肠癌进展中的作用的最新发现，并讨论了其作为生物标志物和新治疗靶点的临床应用。了解调节淋巴管生成的分子途径对于为癌症的新疗法的发展铺平道路是必要的。在未来，包含化疗、其他靶向治疗和抗淋巴管生成药物的组合的定制治疗有望改善患者的预后。这种向临床的进展必须由新的研究途径指导，例如确定预测治疗反应的生物标志物。
Zotero 插件